Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Medrol [legacy through FY23] by Year
Medrol (methylprednisolone) [legacy through FY23] — Worldwide revenues ($M) ($M)
Pfizer Medrol [legacy through FY23]: $61M in FY2023, up 8.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Medrol | 61 | 56 | 9% | 7% | 39 | 36 | 8% | 14% | 106 | 103 | 3% | 5%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Medrol (methylprednisolone) [legacy through FY23] — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 61 | +8.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 56 | -8.2% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 61 | +10.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 55 | -17.9% | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 67 | -9.5% | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2018 | Dec 31, 2018 | 74 | -84.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
| FY2017 | Dec 31, 2017 | 483 | +7.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗ |
| FY2016 | Dec 31, 2016 | 450 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗ |
Breakdown
What makes up medrol [legacy through FY23]
- Medrol (methylprednisolone) [legacy through FY23] — U.S. revenues ($M)39 · FY2023
- Medrol (methylprednisolone) [legacy through FY23] — International revenues ($M)206 · FY2023
- Medrol (methylprednisolone) [legacy through FY23] — Worldwide reported YoY (%)9.0% · FY2023
- Medrol (methylprednisolone) [legacy through FY23] — Worldwide operational (constant-currency) YoY (%)7.0% · FY2023
Cite this data
StockData. (2026). Pfizer Medrol [legacy through FY23] ($M), annual FY2016–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/medrol-leg-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.